knowledge -WSS

knowledge

author：Wikipedia 2025-09-30 17:27:17 - browse：188

Microsoft's head of research Peter Lee speaking at STAT Breakthrough Summit in San Francisco. Sarah Gonzalez for STAT

SAN FRANCISCO — Surging interest in generative AI among medical professionals since ChatGPT’s launch is perhaps a testament to its potential — but it could also lead clinicians, and patients to experiment with it before there is wider consensus on how to navigate its biases and other pitfalls, Microsoft’s head of research Peter Lee said Thursday at STAT’s Breakthrough Summit.

About a month after OpenAI — Microsoft has a significant financial stake in the company — launched its chatbot in 2022 on November 30, which happened to be Lee’s birthday, he got a note from a doctor friend who said he’d used it so his receptionist could file after-visit summaries for patients. While Lee and a handful of other doctors at Microsoft had been impressed with the GPT-4’s capabilities, they knew it had weaknesses.

“The emotions were really mixed. I mean we were thrilled,” he said, but then “just within minutes there’s a feeling of dread. We had already come to the realization that GPT-4 would be prone to issues, issues of bias, hallucination, mathematical and logical errors,” he said. “And so, there’s an immediate question: ‘Should we allow this to happen?’”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： What to watch for from Zogenix and Amicus clinical trials

leisure time

WSS

Senators push IRS to launch nonprofit hospital probe

A new crop of companies is reshaping the health data economy

After Optum profits sink, UnitedHealth makes changes

Aspartame and sugar

Yogurt drink instead of a colonoscopy? CRISPR bacteria are tested

What to know about the judge who will handle the Trump case

focus

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

focus

BioMarin wins approval for gene therapy to treat hemophilia A

Bird flu researchers hone in on Finland’s mink farms

BioMarin wins approval for gene therapy to treat hemophilia A

BMS, looking to build heart drug business, turns to AI for diagnosis

As demand for Covid shots wanes, Moderna seeks its next success

Mark Cuban is blaming the wrong people for high drug costs

ChatGPT in medicine: STAT answers readers' burning questions

Dems pitch expanding Medicare power to negotiate drug prices

Tori Bowie and the unacceptable rates of Black maternal death

Why patients can’t get everything they want on drug pricing

entertainment

The battle over 'scope creep' and who gets to be called 'doctor'

Idaho college killings prosecutors challenge defense's grand jury claims

What it's like to live with paralysis for one psychologist

Device maker Teleflex to acquire urology company for $600M

Biogen says it will cut costs by $700 million, slash 1,000 jobs

Senate panel puts off hardest PBM reforms for another day

hotspot

hotspot

leisure time

knowledge